Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01511432 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects
A Phase 1 study, sponsored by Vertex Pharmaceuticals Incorporated.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
NCT01511432 is a Phase 1 study that has completed, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 64 participants.
The verdict
NCT01511432, a Phase 1 study, has completed, sponsored by Vertex Pharmaceuticals Incorporated.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the relative bioavailability, safety, and tolerability of 3 new formulations of telaprevir relative to the Incivek 375-mg tablets.
Interventions
- DRUG telaprevir formulation A
- DRUG telaprevir Formulation B
- DRUG telaprevir Formulation C
- DRUG telaprevir Formulation D
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2012-01 |
| Est. Completion | 2012-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01511432
The ClinicalTrials.gov registry entry for NCT01511432 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which telaprevir formulation A is the first listed.
NCT01511432 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01511432 about?
NCT01511432 is a clinical study titled "A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects". The purpose of this study is to evaluate the relative bioavailability, safety, and tolerability of 3 new formulations of telaprevir relative to the Incivek 375-mg tablets.
What is the current status of trial NCT01511432?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2012-01. Estimated completion is 2012-07.
What interventions are being tested in trial NCT01511432?
The interventions under investigation include: telaprevir formulation A (DRUG), telaprevir Formulation B (DRUG), telaprevir Formulation C (DRUG), telaprevir Formulation D (DRUG).
Who is sponsoring clinical trial NCT01511432?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.